Page last updated: 2024-09-04

tipifarnib and Diffuse Lymphocytic Lymphoma, Poorly-Differentiated

tipifarnib has been researched along with Diffuse Lymphocytic Lymphoma, Poorly-Differentiated in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (50.00)	29.6817
2010's	1 (50.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bouabdallah, R; Briere, J; Chassagne-Clement, C; De Kerviler, E; Franchi, P; Ghesquieres, H; Haioun, C; Houlgatte, R; Jais, JP; Jardin, F; Raponi, M; Ribrag, V; Rolland, D; Thieblemont, C	1
Barbarat, A; Camara-Clayette, V; Coiffier, B; Ribrag, V; Rolland, D; Salles, G; Thieblemont, C	1

Trials

1 trial(s) available for tipifarnib and Diffuse Lymphocytic Lymphoma, Poorly-Differentiated

Article	Year
Phase II trial and prediction of response of single agent tipifarnib in patients with relapsed/refractory mantle cell lymphoma: a Groupe d'Etude des Lymphomes de l'Adulte trial. Cancer chemotherapy and pharmacology, 2010, Volume: 65, Issue:4 Topics: A Kinase Anchor Proteins; Administration, Oral; Aged; Antineoplastic Agents; DNA-Binding Proteins; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Guanine Nucleotide Exchange Factors; Humans; Lymphoma, Mantle-Cell; Male; Minor Histocompatibility Antigens; Neoplasm Recurrence, Local; Nuclear Proteins; Predictive Value of Tests; Prognosis; Prospective Studies; Proto-Oncogene Proteins; Quinolones; Reverse Transcriptase Polymerase Chain Reaction; Survival Analysis; Treatment Outcome	2010

Article

Year

Phase II trial and prediction of response of single agent tipifarnib in patients with relapsed/refractory mantle cell lymphoma: a Groupe d'Etude des Lymphomes de l'Adulte trial.

Cancer chemotherapy and pharmacology, 2010, Volume: 65, Issue:4

Topics: A Kinase Anchor Proteins; Administration, Oral; Aged; Antineoplastic Agents; DNA-Binding Proteins; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Guanine Nucleotide Exchange Factors; Humans; Lymphoma, Mantle-Cell; Male; Minor Histocompatibility Antigens; Neoplasm Recurrence, Local; Nuclear Proteins; Predictive Value of Tests; Prognosis; Prospective Studies; Proto-Oncogene Proteins; Quinolones; Reverse Transcriptase Polymerase Chain Reaction; Survival Analysis; Treatment Outcome

2010

Other Studies

1 other study(ies) available for tipifarnib and Diffuse Lymphocytic Lymphoma, Poorly-Differentiated

Article	Year
Farnesyltransferase inhibitor R115777 inhibits cell growth and induces apoptosis in mantle cell lymphoma. Cancer chemotherapy and pharmacology, 2008, Volume: 61, Issue:5 Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Farnesyltranstransferase; Female; Humans; Lamin Type A; Lymphoma, Mantle-Cell; Mice; Mice, Nude; Nuclear Proteins; Protein Precursors; Quinolones; Xenograft Model Antitumor Assays	2008

Article

Year

Farnesyltransferase inhibitor R115777 inhibits cell growth and induces apoptosis in mantle cell lymphoma.

Cancer chemotherapy and pharmacology, 2008, Volume: 61, Issue:5

Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Farnesyltranstransferase; Female; Humans; Lamin Type A; Lymphoma, Mantle-Cell; Mice; Mice, Nude; Nuclear Proteins; Protein Precursors; Quinolones; Xenograft Model Antitumor Assays

2008